Business
Bayer Starts Phase IIa Study for Treatment of Patients With Alport Syndrome
BERLIN, December 04, 2025--Bayer announced today initiation of a Phase IIa clinical trial with BAY 3401016, an investigational monoclonal antibody with potential to block a protein called Semaphorin 3A (Sema3A), which is thought to be involved in the progression of kidney damage in Alport Syndrome (AS), a rare genetic disorder. The first-in-patient study, ASSESS, is a randomized, double-blind, placebo-controlled, group-comparison trial (NCT07211685), with an extension phase, which will investiga
About this update from Bayer Ag
[{"type":"list","items":[{"val":[{"type":"text","content":"BAY 3401016 is an investigational monoclonal antibody with potential to block a protein called Semaphorin 3A (Sema3A), which is thought to be involved in the progression of kidney damage in Alport Syndrome (AS), a rare genetic disorder","length":235,"tagName":"p","attribs":{}}]},{"val":[{"type":"text","content":"Bayer explores opportunity to address high unmet medical need of patients suffering from AS and advances research efforts through close cooperation with AS patient organizations","length":177,"tagName":"p","attribs":{}}]},{"val":[{"type":"text","content":"Derived from the strategic research cooperation with Evotec, advancement of BAY 3401016 into ASSESS Phase IIa clinical study is further strengthening Bayer’s development portfolio","length":179,"tagName":"p","attribs":{}}]},{"val":[{"type":"text","content":"The program has received Fast Track Designation and Orphan Drug Designation from the U.S. Food and Drug Administration (FDA)","length":124,"tagName":"p","attribs":{}}]}],"tagName":"ul","bulletedList":true,"length":715,"olType":false},{"type":"text","content":"BERLIN, December 04, 2025--(BUSINESS WIRE)--Bayer announced today initiation of a Phase IIa clinical trial with BAY 3401016, an investigational monoclonal antibody with potential to block a protein called Semaphorin 3A (Sema3A), which is thought to be involved in the progression of kidney damage in Alport Syndrome (AS), a rare genetic disorder. The first-in-patient study, ASSESS, is a randomized, double-blind, placebo-controlled, group-comparison trial (NCT07211685), with an extension phase, which will investigate the efficacy and safety of BAY 3401016 in adult participants with Alport Syndrome.","length":602,"tagName":"p"},{"type":"text","content":""The initiation of the ASSESS trial represents an important milestone for our investigational BAY 3401016 program," said Andrea Haegebarth, Ph.D., Global Head of Research and Early Development for Cardiovascular, Renal, and Immunology at Bayer’s Pharmaceuticals Division. "We are collaborating closely with the patient organization community to gain a deeper understanding of the real challenges faced by people living with Alport Syndrome. We believe BAY 3401016 holds promise as a potential therapeutic approach, and we look forward to assessing its efficacy and safety profi...